GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
This article was originally published in The Tan Sheet
Executive Summary
The generic drug industry should carefully consider any attempt to derail FDA's regulatory approach to Hatch/Waxman reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association